Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 1/20 | 0.43 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.43 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.43 |
| ▸ | CPS1 | P31327 | 1/20 | 0.41 |
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GHSR | Q92847 | 2/20 | 0.38 |
| ▸ | KAT7 | O95251 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | KRAS | P01116 | 2/20 | 0.37 |
| ▸ | SPR | P35270 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21543752 | 1.00 | SMARCA2 (0.43) | SMARCA2SMARCA4PBRM1CPS1SETD7 | |
| SCHEMBL26330343 | 0.89 | SMARCA2 (0.42) | SMARCA2SMARCA4PBRM1CPS1SETD7 | |
| SCHEMBL21531001 | 0.87 | SMARCA2 (0.44) | SMARCA2SMARCA4PBRM1SETD7MAPT | |
| SCHEMBL21531002 | 0.87 | SMARCA2 (0.44) | SMARCA2SMARCA4PBRM1SETD7MAPT | |
| SCHEMBL31745312 | 0.87 | SMARCA2 (0.44) | SMARCA2SMARCA4PBRM1SETD7MAPT | |
| SCHEMBL21542839 | 0.87 | CPS1 (0.42) | CPS1GHSRKRAS | |
| SCHEMBL21542841 | 0.87 | CPS1 (0.42) | CPS1GHSRKRAS | |
| SCHEMBL26330258 | 0.83 | SMARCA2 (0.38) | SMARCA2SMARCA4PBRM1CPS1SETD7 | |
| SCHEMBL21543490 | 0.81 | SMARCA2 (0.37) | SMARCA2SMARCA4PBRM1CPS1GHSR | |
| SCHEMBL21543493 | 0.81 | SMARCA2 (0.37) | SMARCA2SMARCA4PBRM1CPS1GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-02-15 | — | — | US | disclosed |
| EP-3788038-B1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-12-15 | — | — | US | disclosed |
| US-11090304-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2021-08-17 | — | — | US | disclosed |
| EP-3788038-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | Amgen Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | SMARCA2 728/4885SMARCA4 670/4885PBRM1 823/4885 |
| US-11090304-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | SMARCA2 728/4885SMARCA4 670/4885PBRM1 823/4885 |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | SMARCA2 728/4885SMARCA4 670/4885PBRM1 823/4885 |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | SMARCA2 728/4885SMARCA4 670/4885PBRM1 823/4885 |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | SMARCA2 728/4885SMARCA4 670/4885PBRM1 823/4885 |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | SMARCA2 728/4885SMARCA4 670/4885PBRM1 823/4885 |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | SMARCA2 728/4885SMARCA4 670/4885PBRM1 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.